Medication info
Nexiten Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Nexiten Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
LightPharmTech Co., Ltd.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets/box [(14 tablets/Alu-alu X 2)]
Approval status
Active

MFDS item code 201906915 · Approved 2019.09.30

Summary

Main use
Treatment of reflux disease, gastrointestinal symptoms and ulcers (including H. pylori eradication and prevention of rebleeding), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms are relieved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, and heartburn) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective and selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring ongoing administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration. 4. Renal impairment No dose adjustment is necessary. Use with caution, as there is limited experience with administration to patients with severe renal failure. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms are relieved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
LightPharmTech Co., Ltd.

Efficacy & effects

Treatment of reflux disease, gastrointestinal symptoms and ulcers (including H. pylori eradication and prevention of rebleeding), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
  • rebleeding from gastric ulcer
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease, particularly for maintenance therapy to prevent recurrence of erosive reflux esophagitis. It is also effective for the treatment of duodenal ulcers and peptic ulcers in patients with Helicobacter pylori infection and for preventing recurrence. It helps in the treatment and prevention of upper gastrointestinal symptoms and gastric ulcers associated with the use of non-steroidal anti-inflammatory drugs. It is used in the treatment of Zollinger-Ellison syndrome and for maintenance therapy after preventing rebleeding from gastric or duodenal ulcers. This medication is very effective in improving and treating symptoms of gastrointestinal diseases.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms are relieved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, and heartburn) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective and selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring ongoing administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration. 4. Renal impairment No dose adjustment is necessary. Use with caution, as there is limited experience with administration to patients with severe renal failure. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms are relieved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medication should not be used in certain patients. It should not be administered if there is an allergy or history of hypersensitivity to this drug or its components, or to benzimidazoles. Additionally, antibiotics used for the eradication of Helicobacter pylori, such as penicillin or macrolide antibiotics, should not be taken in conjunction with this drug in case of allergy. Patients taking certain heart-related medications or antiviral drugs, as well as nursing women and patients with a history of myocardial infarction, should not use this medication. This drug contains Yellow No. 5 dye and should be used cautiously in patients allergic to this component. Various adverse reactions may occur when taking this drug, thus caution is required. For example, blood-related issues, allergic reactions, electrolyte imbalances, mental symptoms, gastrointestinal problems, skin rashes, muscle pain, etc., may occur. Particularly with long-term use, electrolyte abnormalities such as hypomagnesemia may arise, necessitating regular tests. Since this medication suppresses gastric acid secretion, it may slightly increase the risk of some bacterial infections. Therefore, if diarrhea symptoms persist, consult a physician. Prolonged use at high doses may increase the risk of fractures, so patients at risk of osteoporosis should be cautious. This medication can interact with several drugs, so if taking other medications, it is essential to inform your doctor or pharmacist, particularly regarding care when using in conjunction with warfarin, methotrexate, antiviral drugs, certain antibiotics, clopidogrel, etc. Due to limited safety data regarding this drug during pregnancy, it should be used cautiously, and its use is not recommended during breastfeeding. In the event of overdose, no specific antidote is available, so treatment should be symptomatic, and it should be kept out of reach of children. Lastly, if using this medication for an extended period or if symptoms change, it is advisable to consult a physician and to take the minimum effective dose and duration.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, eosinophilia, drug reaction with systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, black stools, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue swelling, ulcerative stomatitis, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver function abnormalities, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, anorexia, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremor, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, abnormal olfaction, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. To maintain the drug's effectiveness, it should be stored at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets/box [(14 tablets/Alu-alu X 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.